© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
June 16, 2021
Susan Lang, MA, MBA, the CEO of XIL Health and former senior executive with Express Grips, discusses what might happen to independent pharmacies if things continue as they are following the financial difficulties of the pandemic.
June 14, 2021
Susan Lang, MA, MBA, the CEO of XIL Health, discusses how pharmacies that have already been hard hit by the pandemic may be impacted if Pfizer goes through with their projected increased in COVID-19 vaccine prices.
Michael Holden, FRPharmS, FRSPH, associate director of Pharmacy Complete in the United Kingdom, discusses some of the key differences between the role of the pharmacist in the United Kingdom versus the United States.
Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses for the prevention of herpes zoster in adults aged 50 years and older.
June 13, 2021
Because study coordinators were unable to travel, research pharmacist Brian Wortz, PharmD, said researchers were forced to adapt quickly and figure out what they could do remotely.
June 12, 2021
As the drug experts, Brian Wortz, PharmD, said pharmacists may be able to recognize adverse effects before other health care professionals, ensuring patient safety and optimizing their care.
June 11, 2021
Oncologist Susan Miesfeldt, MD, of MaineHealth, discussed the importance of genetic testing and counseling for breast and ovarian cancers as well as barriers that must be addressed in order to reach more patients eligible for these services.
Clinical trial participants often have even more questions than patients receiving standard-of-care treatments, so working within the team to answer their questions and provide optimal care is essential for research pharmacists.
Susan Lang, MA, MBA, CEO of XIL Health and former senior executive at Express Scripts, discusses some of the issues pharmacies are experiencing around staffing to support COVID-19 immunizations and how these issues may change post-pandemic.
Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.